Skip to main content
. 2019 Jan 14;20(2):307. doi: 10.3390/ijms20020307

Figure 4.

Figure 4

Cytokine profiling on PC-3, DU-145, and LNCaP human prostate cancer cells treated with A009. (A) PC-3, DU-145, and LNCaP were treated with A009 or HyT (dilution 1:500 and 1:250) for 6 h, and analyzed for cytokine production by flow cytometry. FACS analysis showed that A009 reduced VEGF, CXCL8, and CXCL12 release on PC-3, DU-145, and LNCaP PCa cell lines. (B) Secretome profiling on DU-145 and LNCaP secreted products, following 24 h treatment with A009 (L3 or L4, dilution 1:250), by BIOPLEX, showed the ability of A009 to inhibit production of VEGF and CXCL8 release in the three PCa cell lines investigated. The was particular strong in LNCap cells. Results are showed as mean ± SEM, ANOVA, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.